# A Study on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-7249 Injection in Healthy Subjects

> **NCT06541457** · PHASE1 · COMPLETED · sponsor: **Fujian Shengdi Pharmaceutical Co., Ltd.** · enrollment: 48 (actual)

## Conditions studied

- Hyperlipidemia

## Interventions

- **DRUG:** HRS-7249 injection
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06541457
- **Lead sponsor:** Fujian Shengdi Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-08-15
- **Primary completion:** 2025-07-30
- **Final completion:** 2025-07-30
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2025-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06541457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06541457, "A Study on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-7249 Injection in Healthy Subjects". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06541457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*